Released Oct 7, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001104659-26-123458
What the release said
Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall Street expectations.
Profound expects preliminary unaudited third-quarter 2026 revenue of $9.8 million to $10.0 million and gross margin to exceed 70%.¶2¶3
Revenue is expected to increase 85% to 89% year over year from $5.3 million in the third quarter of 2025, and 292% to 300% sequentially from $2.5 million in the second quarter of 2026.¶4¶5
Expected revenue is 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, and Profound plans to report full third-quarter results after market close on November 5, 2026.¶3¶6
- Expected total revenue
- $9.8 million to $10.0 million¶2
- Expected year-over-year revenue growth
- 85% to 89% Compared with the third quarter of 2025¶4
- Prior-year revenue
- $5.3 million Third quarter of 2025¶4
- Expected gross margin
- 70% Q3-2026, expected to exceed this level¶3
- Bloomberg mean analyst consensus
- $6.78 million Revenue consensus¶3
- Revenue above consensus
- 45% to 47% Compared with the Bloomberg mean analyst consensus¶3
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 |
|---|---|---|---|
| Revenue | $9.83M | $5.06M | $2.54M |
| Net Income | -$7.72M | -$7.98M | -$9.37M |
| EPS Diluted | -$0.21 | -$0.26 | $0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR